Understanding the science behind DARZALEX FASPRO®

How DARZALEX FASPRO® allows for ~3 to 5 minute administration

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) is a CD38-targeted monoclonal antibody in a subcutaneous formulation. DARZALEX FASPRO® contains recombinant hyaluronidase, which mimics hyaluronidase, a naturally occurring substance that increases permeability of subcutaneous tissue. This makes it possible for 15 mL containing 1,800 mg of daratumumab to be administered in approximately 3 to 5 minutes.1

Recombinant hyaluronidase works locally and transiently to degrade hyaluronan ([HA], a naturally occurring glycosaminoglycan found throughout the body) in the extracellular matrix of the subcutaneous space. It cleaves the linkage between the 2 sugars (N-acetylglucosamine and glucuronic acid) that comprise HA. Recombinant hyaluronidase has a half-life in skin of less than 30 minutes.1

The effects of hyaluronidase are reversible and permeability of the subcutaneous tissue is restored within 24 to 48 hours.1

How daratumumab works

Daratumumab is an immunotherapy that works with the immune system.1

Multiple myeloma cells can go unrecognized by the body, which allows them to grow.

Daratumumab attaches itself to the CD38 protein on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.

Daratumumab directly kills multiple myeloma cells and/or allows the immune system to identify and destroy them. Because of the way daratumumab works, it may also affect normal cells.

DARZALEX FASPRO® can cause serious adverse reactions, including systemic administration-related reactions (ARRs). DARZALEX FASPRO® may increase neutropenia and thrombocytopenia induced by background therapy, therefore monitor complete blood cell counts periodically during treatment.1

Learn more about DARZALEX® (daratumumab) and how it targets CD38